The Opioid Crisis: Effectiveness of State Responses
|
|
- Constance Booker
- 5 years ago
- Views:
Transcription
1 The Opioid Crisis: Effectiveness of State Responses Gordon H. Smith, Esq. Maine Medical Association American Society of Medical Association Counsel Mauna Lani Bay, November 2017
2 Opioids: the difficult truth We know of no other medication routinely used for a nonfatal condition that kills patients so frequently. NEJM: 374; Dosage >200 MME: Number Needed to Kill = 32 Median time to opioid-related death: 2.6 years
3 Maine Led the Nation Maine led the nation in prescribing long acting opioids at 21.8 Rx/100 people. (2014 based on 2012 CDC data) 60 to 65 pills for every man, woman and child in Maine annually.
4 More than One Death per Day in Maine Maine led nation in rate of long-acting opioid prescriptions Overdose death rate in Maine increased 40% from 2015 to Mainers lost to opioid/heroin deaths in overdose deaths in 2016 (313 involving opioids) Projected decrease in 2017 to 330 Contrast: During the last decade, there were 258 homicides in Maine.
5 175 lives lost per year Nationally Over 64,000 overdose deaths in 2016 Contrast: 58,000 American Casualties during Vietnam War.
6 Limited Treatment Options for Opioid Use Disorder or Substance Use Disorder It is estimated that 28,000 Mainers have Opioid Use Disorder with capacity to treat only 3500 to 7000 Nationwide: Only 10.6% of youth and adults who need treatment for SUD receive treatment (From President s Commission Report, November 2017)
7 1,024 Maine Babies Drug Affected in ,013 in 2015 Maine s infant mortality rate (7.1/1000) exceeds the national average 1 out of every 11 babies in Maine was born drug-affected in drug affected babies born each day
8 Evidence of Over-Prescribing C-Section patients 1 53% report taking no or very few (<5) opioid pills prescribed post-operatively 83% report taking half or fewer Thoracic surgery patients 1 45% report taking no or very few (<5) opioid pills prescribed post-operatively 71% report taking half or fewer 1: PLoS One ;11(1); e Epub 2016 Jan
9 Growing Evidence of Over-Prescribing General surgery patients 2 75% partial mastectomy pts did not take any of their prescribed opioids 34% lap choly pts took no prescribed opioids 45% lap inguinal hernia pts took no prescribed opioids Pts reported having 67% to 85% opioid pills remaining Wisdom tooth extraction patients 3 On average, received 28 pills but used <50% of amount prescribed Extrapolates to >100 million opioid pills unused nationally! 2: Ann Surg, Hill et al, Sept 14, : Drug Alcohol Depend Nov 1; Epub 2016 Sep 20.
10 Maine s Response to Opioid Crisis 2002 Educational effects began by state DEA and Maine Medical Association 2013 MaineCare (Medicaid) limits on opioids prescribed for chronic pain 2015 Maine Opiate Collaborative established US Attorney Attorney General Department of Public Safety Staffed by Maine Medical Association Three Task Forces, 22 Community Forums 2016 (March 2016) CDC Guidelines Issued 2016 Enactment of PL 2016 Chapter 488 effective date: July 29, Enactment of PL 2017, Chapter Legislative Task Force Established, Report due December 6, 2017
11 Maine s Response continued Limits on prescribing, including maximum daily dose (100MME) Electronic Prescribing mandate Mandated PMP check Increased use of Naloxone via statutory changes ( ) Medical Board guidelines/rules ( ) Enhanced treatment options, particularly medication assisted treatment (MAT) Prescriber Education; MICIS Live 3 hour programs On-line modules (web-based CME) One hour presentations on Chapter 488 and implementing regulations
12 Overview of Chapter 488 Effective 90 days after adjournment of the Second Regular Session of the 127 th Maine Legislature, though some provisions have other timeframes specified (July 29, 2016) As Amended by P.L. 2017, Chapter 213 As further described by OSAMHS Rule Chapter 11, Rules Governing the Controlled Substances Prescription Monitoring Program and Prescription Opioid Medications Components include: Required PMP check for prescribers and dispensers (1/1/2017) Prescribing limits on MMEs per day (7/29/2016) Prescribing limits on length of scripts (1/1/2017) Exception for emergency rooms, inpatient hospitals, long-term care facilities, or residential care facilities or in connection with a surgical procedure. Exception for medication-assisted treatment for substance use disorder Exceptions for active and aftercare cancer treatment, palliative care, and end-of-life and hospice care Other exceptions may be determined by rule Mandatory CME (12/31/2017) Mandatory electronic prescribing (7/01/2017) Partial filling of prescriptions at patient request (7/29/2016)
13 Required PMP check Prescriber Responsibilities Upon initial prescription of benzodiazepine or opioid medication Every 90 days following Delegation of PMP check Exception Prescribers may delegate PMP check to any staff member duly authorized by prescriber and PMP Office Despite delegation, prescriber must review patient s aggregate MME (including new prescription); number of prescribers currently prescribing controlled substances to patient; and number of pharmacies currently dispensing same Staff members of a group practice of prescribers who are authorized by a designated group practice leader, may check PMP on patients receiving care from the practice. No PMP check is required for benzodiazepine or opioid medication directly administered in an emergency room setting, an inpatient hospital setting, a long-term care facility (assisted living or nursing home), or a residential care facility. No PMP check is required for hospice or end-of-life patients.
14 Prescriber Responsibilities Electronic Prescribing Beginning July 1, 2017, prescribers with the capability to electronically prescribe must prescribe all opioid medication electronically A waiver may be available in some circumstances: Written waiver application required Penalties for failure to comply Continuing Education Every prescriber must complete 3 hours of CME on the prescription of opioid medication every 2 years as a condition of prescribing opioid medication First 3 hours must be completed by 12/31/2017. Beginning in 2018, all MD s must complete the 3 hours of CME regardless of prescribing.
15 Prescriber Responsibilities Required notations on opioid prescriptions Note prescriber s DEA number Note Acute or Chronic on the prescription (including suboxone) On prescriptions for acute on chronic pain (Exemption Code F), use Acute On prescriptions for palliative care (Exemption Code B), note the diagnosis (ICD-10) code On any prescriptions where an exemption is claimed, the exemption code (A through H) must be noted Exemption codes are not required on veterinary prescriptions New: Pharmacists may contact prescribers by telephone to verify and document missing information on the script.
16 Exceptions to limits on opioid medication prescribing By Statute 1. Pain associated with active and aftercare cancer treatment. Providers must document in the medical record that the pain experienced by the individual is directly related to the individual s cancer or cancer treatment. Exemption Code A 2. Palliative care in conjunction with a serious illness (includes injury). Code B, (ICD 10 Code must be included on script as well as Code B ) 3. End-of-life and hospice care. Code C 4. Medication-Assisted Treatment for substance use disorder. (Original 12-month limit has been removed.) Code D
17 Exceptions to limits on opioid medication prescribing By Rule 5. A pregnant individual with a pre-existing prescription for opioids in excess of the 100 Morphine Milligram Equivalent aggregate daily limit. This exemption applies only during the duration of the pregnancy. Code E 6. Acute pain for an individual with an existing opioid prescription for chronic pain. In such situations the acute pain must be postoperative or new onset. The seven day prescription limit applies. Code F 7. Individuals pursuing an active taper of opioid medications, with a maximum taper period of six months, after which time the opioid limitations will apply, unless one of the additional exceptions in this subsection apply; or Code G 8. Individuals who are prescribed a second opioid after proving intolerant to a first opioid, thereby exceeding the 100 MME limit. Neither prescription may exceed 100 MME. Code H
18 Partial fill Upon patient request, pharmacist may dispense lesser quantity of medication than is prescribed Remainder of prescription is void Pharmacist must, within 7 days, notify prescriber of quantity actually dispensed Notification may be by notation in patient s EHR, by electronic transmission or fax or telephone In cases of pharmacist shortage, lesser quantity may be dispensed. Remainder may be dispensed only if within 72 hours.
19 Effective July 1, 2017 E-prescribing Mandate MMA relationship with Dr. First. Contact is Eric Landry at or No exceptions for any specialties, locations Long term care facilities may use fax per DEA rules For homeless patients, use address of shelter, street name, if possible; if no address, may prescribe on paper Exemption from limits/pmp checks is NOT exemption from E- prescribing requirement!
20 E-prescribing Mandate - Exceptions Waiver applications now available Pharmacists not required to verify waivers or exceptions Exceptional circumstances allowing written prescriptions: Valid waiver from PMP Temporary technological or electrical failure To be dispensed by VA or Indian Health Service pharmacy, or outside Maine Prescriber reasonably determines that it would be impractical, patient could not obtain medication timely, and delay would adversely impact patient s medical condition
21 Licensing Board Response Licensing Boards, Joint Rule Chapter 21 amendments Universal precautions Urine screens Random pill counts Treatment agreement MaineCare Rules Board of Licensure in Medicine, Chapter 1 Rule amendments Mandatory CME requirement may be broadened to all physicians, regardless of whether opioids are prescribed
22 Impact of Response 3 consecutive-year decline in number of opioid scripts totaling 21.5% (4 th largest decline in the country) 1 year decline in overdose deaths (2017) 2017 Anthem announces 15% decline in opioid prescribing for their insureds in the state.
23 Additional MMA Activities MMA receives annual funding ($150-$250,000) from state to offer prescriber education (MICIS). Two thousand prescribers reached in 2017) EVP serves on Legislature s Task Force to Address Opioid Crisis (2017) MMA, through grants staffed Maine s Opioid Collaborative and hosted twenty-two community forums (2016). Funded partially by Maine Health Access Foundation and Maine Community Foundation. Most recent efforts focused on increasing treatment options and advocating for insurance coverage of more non-pharmacological options for treating pain. Support for making naloxone more widely available Support for more detox beds
24 The Future Attorney General and community litigation against Pharma Malpractice cases against prescribers More legislation and regulation President s Commission 56 recommendations (November, 2017) But will there be funding? More efforts re treatment and prevention
25 Resources MMA s Opioid Crisis page: Opioid laws & rules, Maine Opiate Collaborative task force Reports, CDC guidelines, naloxone, Q and A, DHHS clarifications. Caring for ME page: Webinars, opioid laws & rules, information on pain management and tapering, etc.
26 Questions? Maine Medical Association 30 Association Drive, P.O. Box 190 Manchester, Maine Fax Cell #
Caring for ME Lunch & Learn Webinar Opioid Prescribing Regulations Updates on Chapter 488 and Related Rules
Caring for ME Lunch & Learn Webinar Opioid Prescribing Regulations Updates on Chapter 488 and Related Rules Gordon H. Smith, Esq. January 23, 2018, 12-1 pm Audio is available through your computer speakers
More informationUpdate on Maine Laws and Associated Rules on Prescribing Opioid Medication
Update on Maine Laws and Associated Rules on Prescribing Opioid Medication Gordon H. Smith, Esq. Executive Vice President Maine Medical Association 2018 Disclosure There are no significant or relevant
More informationUpdate on Maine Laws and Associated Rules on Prescribing Opioid Medication
Update on Maine Laws and Associated Rules on Prescribing Opioid Medication Gordon H. Smith, Esq. Executive Vice President Maine Medical Association 2018 Disclosure There are no significant or relevant
More informationPrescription Monitoring Program (PMP)
06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid
More informationMaine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers
Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers Gordon H. Smith, Esq., Executive Vice President Maine Medical Association May 3, 2016 Facing the Opioid Crisis Today Opioid
More informationCaring for ME Pharmacy Lunch & Learn Webinars
Caring for ME Pharmacy Lunch & Learn Webinars Opioid Prescribing Regulations : Updates on Chapter 488 and Related Rules Audio is available through your computer speakers For audio by phone, call 1-646-558-8656
More informationMaine s Response to the Opiate Crisis. Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016
Maine s Response to the Opiate Crisis Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016 Required Disclosure Text Font typically Times New Roman at least 20 point Try
More information2016 Dr. Douglas H. Kay CPE Symposium
GREGORY CAMERON, R.Ph ASSISTANT PROFESSOR OF PHARMACY PRACTICE FIELD COORDINATOR COMMUNITY SITES HUSSON UNIVERSITY SCHOOL OF PHARMACY November 5, 2016 Please Silence All Electronic Equipment OBJECTIVES
More informationMICIS 2017 REPORT January 1 - December 31, 2017
MICIS 2017 REPORT January 1 - December 31, 2017 MICIS, the Maine Independent Clinical Information Service, has been providing evidence-based prescribing education in Maine since 2008. 2017 Program The
More informationProgress Report and 2018 Legislative Opportunities. Maine Opiate Collaborative Recommendations
Progress Report and 2018 Legislative Opportunities related to the Maine Opiate Collaborative Recommendations April 2018 A. Destigmatize substance use disorders within the law enforcement profession 1.
More information3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationOpioid Prescribing Improvement Program
Opioid Prescribing Improvement Program Jeff Schiff, MD, MBA, Medical Director of Minnesota Health Care Programs Sarah Rinn, MPH, Opioid Prescribing Improvement Program Coordinator Agenda Opioid Prescribing
More informationBuilding a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine
Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine Scott M. Gagnon, MPP, PS-C Director, AdCare Educational Institute of Maine, Inc. Co-Chair, Prevention & Harm
More informationGENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW HOUSE BILL 243
GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW 2017-74 HOUSE BILL 243 AN ACT STRENGTHENING OPIOID MISUSE PREVENTION BY EXTENDING STANDING ORDERS FOR OPIOID ANTAGONIST TO COMMUNITY HEALTH GROUPS;
More informationOpioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
More informationThe Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
More information2. Is this request for a preferred medication? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationProgress Report Maine Opiate Collaborative Recommendations. on the. October 2018
Progress Report on the 2016 Maine Opiate Collaborative Recommendations October 2018 MAINE OPIATE COLLABORATIVE PROGRESS REPORT Prevention & Harm Reduction October 2018 RECOMMENDATIONS STRATEGIES 2018 LEGISLATIVE
More informationMedicaid and the Opioid Crisis
Medicaid and the Opioid Crisis Erica Floyd Thomas Bureau Chief of Medicaid Policy Agency for Health Care Administration Presented to: Medical Care Advisory Committee March 20, 2018 1 Florida Medicaid Covers
More informationSTATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.
STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. Arizona Corporate Counsel Presentation May 8, 2018 Agenda 1. Overview of the Opioid
More informationNew Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers
CENTERS FOR MEDICARE & MEDICAID SERVICES New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers Background CMS understands the magnitude of the nation s opioid epidemic and
More informationWHAT YOU NEED TO KNOW TO ABOUT AB 474
WHAT YOU NEED TO KNOW TO ABOUT AB 474 PRESENTED BY: NEVADA STATE BOARD OF OSTEOPATHIC MEDICINE 2275 Corporate Circle, Suite 210 Henderson, NV 89074 702-732-2147 Fax 702-732-2079 Web Site: www.bom.nv.gov
More informationOPIOID. Opioid Legislation FAQs NEED TO KNOW
OPIOID MICHIGAN OSTEOPATHIC ASSOCIATION APRIL 5, 2018 NEED TO KNOW Opioid Legislation FAQs These FAQs represent a compilation of questions received from MSMS and MAFP members. Please note that this is
More informationGENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH20012-MGfa-35H* (01/26)
H GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH0-MGfa-H* (01/) H.B. Mar, HOUSE PRINCIPAL CLERK D Short Title: Strengthen Opioid Misuse Prevention (STOP)Act. (Public) Sponsors: Referred to:
More informationOPIOID PRESCRIBING RULES. May 17, 2017 Webinar
OPIOID PRESCRIBING RULES May 17, 2017 Webinar Outline Introduction and Universal Precautions Dr. Levine, Commissioner, Health Department 15 Minutes Acute Pain Dr. Patti Fisher, UVMMC 20 Minutes Chronic
More informationMedicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists
CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists Background Opioid medications are effective at treating certain types of pain,
More informationObjectives 1/25/18. An Update on Controlled Substance Prescribing Laws & Rules for CNMs. Exclusionary Formulary Effective: May 17, 2017
1/25/18 An Update on Controlled Substance Prescribing Laws & Rules for CNMs Keeley Harding, DNP, APRN, CPNP-AC/PC February 4, 2018 2018 Ohio ACNM Forward Kalahari Resorts and Conference Center, Sandusky,
More informationOCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES
TITLE 16 CHAPTER 10 PART 14 OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES 16.10.14.1 ISSUING AGENCY: New
More informationCalifornia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationVIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC
1 VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC Virginia Association of Counties November 14, 2016 The Honorable William A. Hazel, Jr., M.D. Secretary of Health and Human Resources 1999 - Estimated drug
More informationPROPOSED AMENDMENTS TO HOUSE BILL 3440
HB 0- (LC ) // (MBM/ps) Requested by Representative WILLIAMSON PROPOSED AMENDMENTS TO HOUSE BILL 0 1 On page 1 of the printed bill, line, delete 1A. and. Delete lines through and pages through and insert:
More informationPrescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
More informationNM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 218 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau
More informationSection I. Short-acting opioid Prior Authorization Criteria
Request for Prior Authorization for Opioid analgesics Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 Requests for opioid analgesics may be subject to prior authorization
More informationIt Takes A Village to Curb the Prescription Opioid Epidemic: Supply healthcare providers with resources to improve patient safety
Session L6 This presenter has nothing to disclose It Takes A Village to Curb the Prescription Opioid Epidemic: CDC Efforts Jan Losby, PhD Team Lead, Overdose Prevention Health Systems Team Division of
More informationOpioid epidemic and PEHP
Opioid epidemic and PEHP Agenda Overview of opioid crisis Utah perspective PEHP: clinical interventions Impact of interventions Why are we here? In the 1990s, the medical establishment came to believe
More informationSUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy
SUBHEAD GOES HERE Addressing Tennessee s Opioid Crisis Natalie A. Tate, PharmD Vice President, Pharmacy Our opioids story Our approach Our response to neonatal abstinence syndrome Facts and faces of opioid
More informationImpact of Opioid Prescribing Rules in Post Acute and Long Term Care
Impact of Opioid Prescribing Rules in Post Acute and Long Term Care Jessica Van Fleet-Green, MD, FAAFP, CMD Chief Medical Officer, Physicians of Southwest Washington Medical Director, ManorCare Lacey History
More informationThe Wisconsin Prescription Drug Monitoring Program
The Wisconsin Prescription Drug Monitoring Program DHS 2018 WI Opioid Forum April 12, 2018 Learning Objectives 1. How the WI epdmp supports healthcare professionals in making informed prescribing, dispensing
More informationbtute PUBLIC CHAPTER NO. 1039
btute of @ennennee PUBLIC CHAPTER NO. 1039 HOUSE BILL NO. 1831 By Representatives Hawk, Gasada, Kumar, Johnson, Gameron Sexton, Terry, Powers, Coley, Daniel, Eldridge, Holsclaw, Favors, Hardaway Substituted
More informationNM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 217 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau
More informationThe Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.
The Wisconsin Prescription Drug Monitoring Program Wisconsin Nurses Association Jail Health Care Conference May 21, 2018 WI PDMP Timeline PDMP Overview January 2013 WI PDMP operational April 2017 WI epdmp
More informationRhode Island. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Rhode Island Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationPRESCRIBING GUIDELINES
Ohio Department of Health RESPONSE TO OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: PRESCRIBING GUIDELINES MIPA CONFERENCE PREVENTING INJURY: FROM RESEARCH TO PRACTICE TO PEOPLE SEPTEMBER 30, 2013 Christy
More informationReport to the Legislature: Impact of the Minnesota Prescription Monitoring Program on Doctor Shopping
Minnesota Board of Pharmacy Report to the Legislature: Impact of the Minnesota Prescription Monitoring Program on Doctor Shopping Prepared By: Dr. Katrina Howard, PMP Pharmacist Consultant October 31,
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationHHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder
HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder Brett Giroir, U.S. Department of Health and Human Services Join the conversation at #OUDTreatment #EndTheStigma Expanding
More informationOklahoma. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More information4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update
Bureau of Professional Licensing MAPS Updates & Opportunities April 28, 2018 Presented by Andrew Hudson, Manager Haley Winans, Analyst Drug Monitoring Section Bureau of Professional Licensing BPL-MAPS@Michigan.gov
More informationThe Opioid Epidemic: The State of the State
JOINT LEGISLATIVE COMMITTEE ON HEALTH AND HUMAN SERVICES The Opioid Epidemic: The State of the State Dr. Mandy Cohen, Dr. Susan Kansagra Department of Health and Human Services Nov. 14, 2017 3 PEOPLE DIE
More informationUnderstanding Maine s Medical Marijuana Law
Understanding Maine s Medical Marijuana Law Maine Pharmacy Association May 20, 2011 Background 1999: Maine Medical Marijuana Act passes as initiated bill (I.B.) Authorizes medical use of marijuana for
More informationPublic Health Impacts of 2016 West Virginia Legislation
Public Health Impacts of 2016 West Virginia Legislation Sherri A. Young, DO, FAAFP WVSOM Summer Seminar North Myrtle Beach, South Carolina June 15, 2016 1 Objectives Passage and implementation of Expedited
More informationBriefing on ARTS to Secretary Hazel October 2017
Agenda -DMAS -DBHDS -VDH -Final discussion Briefing on ARTS to Secretary Hazel October 2017 http://www.dmas.virginia.gov/ 1 Medicaid Addiction and Recovery Treatment Services (ARTS) Partial Hospitalization
More informationRULE-MAKING ORDER PERMANENT RULE ONLY. CR-103P (December 2017) (Implements RCW )
CODE REVISER USE ONLY RULE-MAKING ORDER PERMANENT RULE ONLY CR-103P (December 2017) (Implements RCW 34.05.360) Agency: Department of Health- Dental Quality Assurance Commission Effective date of rule:
More informationCDC Guideline for Prescribing Opioids for Chronic Pain
National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain John Halpin, MD, MPH Medical Officer Division of Unintentional Injury Prevention Prescription Drug
More informationNorth Dakota Board of Pharmacy
North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives
More informationBOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director
BOARD OF PHARMACY- REGULATORY UPDATE Kimberly Grinston, J.D., Executive Director Disclosure and Conflict of Interest I declare no conflicts of interest, real or apparent, and no financial interest in any
More informationTennessee. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationOpioid Abuse and Prescribing. Dr. Mitchell Mutter Director of Special Projects
Opioid Abuse and Prescribing Dr. Mitchell Mutter Director of Special Projects Auburn University February 22, 2019 Disclosure Statement of Financial Interest I, Mitchell Mutter, DO NOT have a financial
More information2125 Rayburn House Office Building 2125 Rayburn House Office Building Washington, DC Washington, DC 20515
The Honorable Greg Walden Chairman Ranking Member 2125 Rayburn House Office Building 2125 Rayburn House Office Building Washington, DC 20515 Washington, DC 20515 Chairman Ranking Member Subcommittee on
More informationTN Opioid Program. Erica Schlesinger, Pharm.D
TN Opioid Program Erica Schlesinger, Pharm.D Nothing to disclose Disclosures TN Together Governor Haslam s Plan Prevention Establishes limits, decreases supply and dosage of prescription opioids Limits
More informationCynthia B. Jones, Director Department of Medical Assistance Services (DMAS)
Department of Medical Assistance Services 600 East Broad Street, Suite 1300 Richmond, Virginia 23219 MEDICAID MEMO http://www.dmas.state.va.us TO: All Prescribing Providers, Pharmacists, and Managed Care
More informationDRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT
c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended
More informationVermont. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Vermont Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of
More informationNC General Statutes - Chapter 90 Article 5E 1
Article 5E. North Carolina Controlled Substances Reporting System Act. 90-113.70. Short title. This Article shall be known and may be cited as the "North Carolina Controlled Substances Reporting System
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More informationOur Journey to Addressing the PA PDMP Program. Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System
Our Journey to Addressing the PA PDMP Program Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System 1 Geisinger Health System Geisinger Health System is an integrated
More informationD. Todd Bess, PharmD 1
s Program as a Tool to Improve Patient Care and Fight the Drug Epidemic D. Todd Bess, Pharm.D. Director April 12, 2018 Disclosure Information I have no financial relationships to disclose. I will not discuss
More informationLouisiana. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationOpioids: What You Should Know About Opioid Prescribing. Denis G. Patterson, DO Nevada State Medical Association October 19, 2016
Opioids: What You Should Know About Opioid Prescribing Denis G. Patterson, DO Nevada State Medical Association October 19, 2016 Contact Information Denis G. Patterson, DO Nevada Advanced Pain Specialists
More informationCLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics
Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationOpioid Review and MAT Clinic CDC Guidelines
1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are
More informationPolicy and Political Dynamics of the Opioid Addiction Crisis in the United States
Policy and Political Dynamics of the Opioid Addiction Crisis in the United States Mark W. Parrino, M.P.A. July 21, 2018 15 th Annual Midwest Conference on Problem Gambling and Substance Abuse Hilton Kansas
More informationOregon Opioid Overdose Prevention Initiative
Oregon Opioid Overdose Prevention Initiative Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Association of Hospitals & Health Systems February 2017
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Alaska Requires adoption of regulations that provide that a practitioner query the PDMP prior to dispensing, prescribing, or administering a Sch. II or III controlled substance; query is not required for
More informationMOA: Practice Managers Program. Presented by: Kimber Debelak, CMC, CMOM, CMIS. May 17, zpain Management. & New Opioid Laws
MOA: Practice Managers Program Presented by: Kimber Debelak, CMC, CMOM, CMIS May 17, 2018 Pain Management & New Opioid Laws Objectives and Educational Statement Objectives To understand the need for new
More informationManaging Opioid Overutilization Challenges
One Source. Lower Cost. Better Care. Managing Opioid Overutilization Challenges A LOOK AT REDUCING OPIOID OVERUTILIZATION BY 36 PERCENT Copyright 2017 MedImpact Healthcare Systems, Inc. All rights reserved.
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid
More informationMedicare Part D Opioid Policies for 2019 Information for Patients
CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare Part D Opioid Policies for 2019 Information for Patients Introduction Prescription opioid pain medications like oxycodone (OxyContin ), hydrocodone (Vicodin
More informationTri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary
Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon 2016 Executive Summary 20.8 million people in the United States have a substance use disorder (not limited to opioids), equivalent
More informationISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque, NM. [ NMAC - N, ; A, ]
TITLE 16 CHAPTER 19 PART 26 OCCUPATIONAL AND PROFESSIONAL LICENSING PHARMACISTS PHARMACIST PRESCRIPTIVE AUTHORITY 16.19.26.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque,
More informationBlue Cross of Idaho Addresses State s Opioid Issue
Blue Cross of Idaho Addresses State s Opioid Issue BY THE NUMBERS - Opioid Management page 3 THE PROBLEM - How Preventing Pain Hurt Us page 4 THE SOLUTIONS - Idaho State Board Of Pharmacy Prescription
More informationRevised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
More informationOpioid Epidemic Update & Policy Discussion. Disclosures
Opioid Epidemic Update & Policy Discussion Pete Wertheim, MS Executive Director Disclosures None Call to Action In 2016, the Arizona Department of Health Services reports 790 people died as a result of
More informationOvercoming the Substance Abuse Epidemic: One Member at a Time
Overcoming the Substance Abuse Epidemic: One Member at a Time Innovation and Partnerships: our keys to success Sosunmolu Shoyinka, M.D., FAPA Medical Director for Substance Use Disorders, Centene Corporation.
More informationMARYLAND BOARD OF PHARMACY
MARYLAND BOARD OF PHARMACY CONTRACEPTION REGULATIONSAnd Other Legislative Initiatives THE ROAD FROM CONCEPTUALIZATION TO IMPLEMENTATION Deena Speights-Napata Executive Director Maryland Board of Pharmacy
More informationThe Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose
The Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose 1 Learning Objectives Identify pain treatment related regulatory agencies Discuss the changing role of regulatory
More informationThe STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018
The STOP Measure Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018 AHIP s Safe, Transparent Opioid Prescribing (STOP) Initiative Methodology
More informationIllinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program
Illinois Prescription Monitoring Program Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program Agenda Provide an overview of the Illinois Prescription Monitoring Program
More informationPrescription Drug Abuse National Perspective
Prescription Drug Abuse National Perspective Timothy P. Condon, Ph.D. Science Policy Advisor Office of the Director White House Office of National Drug Control Policy Commonly Abused Prescription Drugs
More informationLiterature year in review: Fast take
Literature year in review: Fast take Fatal opioid overdoses have declined in parts of Eastern Mass. By Catie Edmondson GLOBE CORRESPONDENT AUGUST 11, 2017 EMS program called First Watch: Alert to district
More informationSub. S.B. 119 As Passed by the Senate
AM3404 Sub. S.B. 119 As Passed by the Senate Topic: Opioid Data and Communication Expansion Act moved to amend as follows: In line 1 of the title, after "4723.52," insert "4729.01, 4729.44, 4729.75, 4729.79,
More informationPain: Assessment, Non-Opioid Treatment Approaches and Opioid Management
Quality Improvement Support: Pain: Assessment, Non-Opioid Treatment Approaches and Opioid Management The Aims and Measures section is intended to provide protocol users with a menu of measures for multiple
More informationChanging Course: statewide efforts to combat the opioid epidemic in California
Changing Course: statewide efforts to combat the opioid epidemic in California Kelly Pfeifer, MD kpfeifer@chcf.org April 26, 2018 State of Reform conference STAT Special Report: 52 weeks, 52 faces Obituaries
More informationBackground. CMS finalized new policies for Medicare drug plans to follow starting on January 1,2019.
Background CMS finalized new policies for Medicare drug plans to follow starting on January 1,2019. These policies involve further partnershipwith providers and prescription drug plans. Providers are in
More informationReadopt with amendment Med 502, effective (Document #11090), to read as follows:
Adopted Rules 11-2-16 1 Readopt with amendment Med 502, effective 5-3-16 (Document #11090), to read as follows: PART Med 502 OPIOID PRESCRIBING Med 502.01 Applicability. This part shall apply to the prescribing
More informationThe Challenges of Opioid Dispensing
The Challenges of Opioid Dispensing William R. Kirchain, PharmD, CDE XULA Instructor, Pharmacy Law President, Louisiana Pharmacists Association CDC Guideline for Prescribing Opioids for Chronic Pain United
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Alabama Requirements for use of the PMP, including the following: 1) when prescribing a patient a controlled substance of more than 30 MME per day, physicians shall query the PMP for that patient at least
More information